Danaher Corporation incorporates science and technology and has a market cap of $150B. Click here to read why I rate DHR ...

Danaher has good medium to long-term revenue and margin growth prospects, and the valuation is lower than historical levels.

Loomis Sayles & Co. L.P. boosted its stake in Danaher by 6.2% in Q4, acquiring nearly 60,000 more shares and bringing its ...

Tariff uncertainty and a flagging tech trade have dragged the benchmark S&P 500 lower to start 2025.

We recently published a list of Top 10 Stocks to Buy According to Akre Capital Management. In this article, we are going to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Since you last spoke with The Wall Street Transcript in 2022, your company has gone through some significant changes, including a name change. Can you fill us in on those changes? Richard Warzala: The ...

Guggenheim lowered the firm’s price target on Danaher (DHR) to $250 from $275 and keeps a Buy rating on the shares. The firm adjusted models ...

Let’s dig into the relative performance of Bio-Techne (NASDAQ:TECH) and its peers as we unravel the now-completed Q4 research ...

Akre Capital Management follows a disciplined investment philosophy centered around identifying exceptional businesses ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

Royal London Asset Management Ltd. trimmed its position in Danaher by a mere 0.5%, selling just 1,565 shares in Q4. Despite ...